Larotinib Mesylate

甲磺酸莱洛替尼

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameLarotinib Mesylate
Drug Alias NameZ-650
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK2 inhibitorsTyrosine-protein kinase BTK inhibitorsTyrosine-protein kinase Blk inhibitors +[7] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Receptor protein-tyrosine kinase erbB-4 +[8] 
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsEsophageal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSunshine Lake Pharma Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEsophageal NeoplasmsEsophageal Squamous Cell Carcinoma
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A